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Abstract
Background: Human respiratory syncytial virus (hRSV) is ubiquitous and causes respiratory diseases in both children
and adults. Worldwide, hRSV pneumonia is the second cause of postnatal infant death after malaria. Given the high
impact in terms of morbidity, mortality and costs, especially in the pediatric population, hRSV is recognized as a
global health problem and the WHO, in view of the availability of new vaccines, has urged an active surveillance
program of virus-related infections. The aim of this study has been to evaluate the impact of hRSV infections in the
Italian population, particularly the pediatric one, in terms of hospitalizations.
Methods: In the period 2001–2014, Hospital Discharge Records (HDRs) with the following diagnosis codes included
in the primary diagnosis were evaluated: 466.11 (hRSV bronchiolitis), 480.1 (hRSV pneumonia) and 796 (hRSV). HDRs
were supplied by the National Archive of HDRs data, Ministry of Health.
Results: During the period 2001–2014, 57,656 hospital admissions due to hRSV pathologies were performed. Most
hospitalizations (88.8%) involved patients with less than 1 year of age. Considering only primary diagnosis, 93% of
the admissions were due to bronchiolitis, 5% to pneumonia and 2% to not otherwise specified hRSV infections. In
the period 2001–2014, the hospitalization rate in 0–2 years old children, was equal to 224.8, 9.6 and 4.6/100,000 for
hRSV bronchiolitis, hRSV pneumonia and not otherwise specified hRSV infection, respectively.
Conclusions: This study confirms the high impact of hRSV on the pediatric population in the age class 0–4 years,
with a peak in the first 12 months of life. Most hospitalizations were urgent, although the duration of the hospital
stay was for the most part less than a week, with ordinary discharge at home. Pending the conclusion of ongoing
clinical trials on different hRSV vaccine types, it is extremely important to have updated data on the impact of
hRSV-related pathologies in the various age groups.
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Background
Human respiratory syncytial virus (hRSV), belonging to
the Paramyxoviridae family, is ubiquitous and causes re-
spiratory diseases in both children and adults [1].
In early childhood, it is the main etiologic agent of
infections of the lower respiratory tract and is related to
several clinical pictures such as bronchiolitis, pneumo-
nia, ashmatic bronchitis. Bronchiolitis is the most com-
mon respiratory infection in < 1 year of age children and
is the main cause of hospitalization in the youngest
child, especially during the winter season [2].
hRSV infection can have a serious course especially in
< 3 months of age children or in children with particular
risk factors; it can require hospitalization in Intensive
Care Unit and need for respiratory care [3]. The major
risk factors for severe bronchiolitis caused by hRSV
include preterm birth with or without chronic pulmon-
ary disease, congenital heart disease, Down’s syndrome,
neuromuscular disorders and immunodeficiencies [4];
the same risk factors are often related to a higher rate of
hRSV-related hospitalization [5]. It has also been shown
a correlation between the composition of the nasopha-
ryngeal microbiota (in particular if this latter is
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characterized by Haemophilus influenzae and Streptococ-
cus) and the severity of the disease [6].
In adults, instead, hRSV infection may, in the majority
of cases, cause a mild inflammation of the upper respira-
tory tract or may be completely asymptomatic. Differently,
in the elderly and in high risk adults (affected by chronic
obstructive pulmonary disease, asthma, congestive heart
failure, ect.), hRSV may cause a disease similar to that of
non-pandemic influenza A [7].
In developed countries, pediatric mortality due to
hRSV is low, but not nothing; the situation is completely
different in developing countries, where the annual glo-
bal number of deaths among < 5 years of age children is
66,000–199,000 and 28,000–111,500 for hRSV and influ-
enza, respectively [8]. Worldwide, hRSV pneumonia is
the second cause of postnatal infant death after malaria,
causing 137,000 deaths each year (equal to 6.7% of all
newborn deaths) [9].
The “RSV Observatory” study, has shown that hRSV
infection in Italy presents a seasonal trend and, as described
in other temperate countries, epidemics generally occur
during the colder months of the year January–March) [10].
In the United States, from 1993 to 2008, a
hospitalization rate due to hRSV infection equal to 55/
100,000 person-years was recorded; this value is slightly
lower than that for flu-related hospitalizations virus (65/
100,000/year). In the < 2 years of age pediatric population
these rates increase to 2345 admissions/100,000 and 151/
100,000 person-years for hRSV and influenza, respectively
[11]. These data show that, in the USA, every winter,
hRSV is responsible for 1–2% of admission in < 2 years of
age children. Quite similar data are recorded in Europe
[12]. hRSV causes more hospital admissions than flu even
in older children. In the USA, it is estimated that every
year 1 out of 13 < 5 years of age children requires medical
attention due to a hRSV infection [13].
In addition to ribavirin, other drugs are not currently
licensed. However, transmission of the infection may be
controlled by adequate hygienic measures and prophy-
laxis with Palivizumab [14]. The latter is a humanized
monoclonal neutralizing antibody, produced by recom-
binant DNA technology, directed against the preserved
epitope of the viral fusion glycoprotein, but its efficacy
as well as costs are quite high [15–18]. Therefore, it is
necessary to identify subjects at risk and to define the
methods of administration to ensure a proper use of
health resources [19].
Vaccination could be the most effective preventive
measure, but, at the moment, different vaccine types are
still under development [20–22].
Given the high impact in terms of morbidity, mortality
and costs, especially in the pediatric population, hRSV is
recognized as a global health problem and the World
Health Organization (WHO), in view of the availability
of new vaccines, has urged an active surveillance pro-
gram of virus-related infections [23, 24].
Taking into account the unavailability of specific noti-
fication data for hRSV-related diseases and the possible
future preventive opportunities with new vaccines, the
purpose of this study has been to evaluate the impact of
hRSV infections in the Italian population, particularly
the pediatric one, in terms of hospitalizations in the
period 2001–2014.
Methods
The Hospital Discharge Record (HDR) was officially
established in 1991 (Decree of the Ministry of Health of
28 December 1991) with the aim of providing a sum-
mary of the key information contained in the clinical
record. HDRs represent the information gathering tool
for each patient discharged by national public and pri-
vate hospitals and include information on both clinical
and organizational aspects of hospitalization. The coding
of clinical information included in each HDR is done
through the ICD9-CM coding system (International
Classification of Disease, 9th Revision, Clinical Modifica-
tion), currently used in Italy. For this retrospective study,
HDRs were required for all hRSV-related pathologies for
the period 2001–2014.
In detail, hospitalizations with the following ICD9-CM
diagnosis codes included in the primary diagnosis were
evaluated: 466.11 (hRSV bronchiolitis), 480.1 (hRSV
pneumonia) and 796 (hRSV).
Data processing was performed through the Microsoft
Excel 2007 Software and JMP for statistical analysis.
Resident population data for each given year (available
on the National Statistics Institute, ISTAT, website) were
used for calculating rates.
HDRs were supplied by the National Archive of
HDRs data, Ministry of Health, General Directorate
of Healthcare Planning, VI Office. For this type of
retrospective study formal consent is not required;
any personal data was protected accordingly to the
Helsinki Declaration and to the Italian law (Legislative
Decree of 30 June 2003, n. 196. Code on the protection of
personal data).
Results
From the analysis of the database provided by the Ministry
of Health, it emerged that in Italy, during the period
2001–2014, 57,656 hospital admissions due to hRSV path-
ologies were performed. Males were more represented
than females (55.1% vs. 44.9%, p < 0,001).
Most hospitalizations (88.8%) involved patients with
less than 1 year of age; 8.2% of hospital admissions per-
tained to the 1–4 years age class. The distribution of
hospitalizations remained substantially unchanged in the
various examined years (Fig. 1). With regard to
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individual years, the trend of hospitalizations is charac-
terized by a slightly increase over time, with periodic
fluctuations and a peak in 2012, when 8.6% of all hos-
pital admissions in the studied period were registered.
The hospitalization procedure was mainly urgent (89.3%
of cases) and the duration of stay was mainly (79.5% of
cases) less than one week. Interestingly, duration of stay
resulted independently associated with age class: the
average hospitalization period increased from 5 days in
children aged 0–14 years to 10 days in elderly aged >
74 years. The discharge method was mainly the ordinary
one at home (96.4% of cases). In 0.1% of cases the pa-
tient died, 22.9% of which with less than 1 year of age
and 58.4% aged > 64 years. The 1.7% of all hRSV-related
hospitalizations registered in the period 2001–2014 in-
volved infants (< 28 days of life). Lombardy, followed by
Emilia-Romagna, was the region with the highest
hospitalization rate: the distribution of hospitalizations
due to hRSV was not uniform among regions, with a
statistically significant prevalence (p < 0,001) of northern
regions over central and southern ones, due to an aver-
age age of hospitalized subjects in northern regions
lesser than that observed in central and southern
regions.
Figure 2 shows hospitalization rates by age group; the
< 1 year age class is the one with the highest
hospitalization rate (674/100,000 subjects).
Considering only primary diagnosis, 93% of the admis-
sions were due to bronchiolitis, 5% to pneumonia and
2% to not otherwise specified hRSV infection. Figure 3
shows the distribution of hospitalization due to different
diagnosis, stratified by age class.
Since the age most affected subjects were 0-1 and
2 years old children (bronchiolitis mainly affects children
< 2 years of age), a more in-depth evaluation of this age
group was performed. In the period 2001–2014, out of a
total of 54,661 hospitalized children between 0 and
2 years, 93% were less than one year old and 23.5% of
them were 2 months old.
The most represented diagnosis is hRSV bronchiolitis,
even among younger children (94%). Considering the
first year of life, the distribution of cases accordingly to
different diagnosis per month of age shows the highest
number of cases in the second month of life.
Fig. 1 Hospitalization trend, stratified by age class and year of hospital admission
Fig. 2 Hospitalization rate (per 100,000) stratified by age class
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In the period 2001–2014, the hospitalization rate in 0–
2 years old children, was equal to 224.8, 9.6 and 4.6/
100,000 for hRSV bronchiolitis, hRSV pneumonia and
not otherwise specified hRSV infection, respectively.
Discussion
This study confirms the high impact of hRSV on the
pediatric population in the age class 0–4 years, with a
peak in the first 12 months of life. Most hospitalizations
were urgent, although the duration of the hospital stay
was for the most part less than a week, with ordinary
discharge at home. Only 0.1% of the hospitalized pa-
tients died.
Despite being a public health problem worldwide,
there are limited data on infant mortality for RSV. A re-
cent systematic review showed that 99% of deaths con-
cerned subjects from developing countries; the main risk
factors in these children included: the presence of co-
morbidities, especially congenital heart disease (28% of
cases) and prematurity; the majority of died children re-
ceived mechanical ventilation, which reflects the low
level of quality of care in these countries. Moreover, in-
tensive pediatrics was available only for 24% of children,
and this further underlines that increase in child mortal-
ity is affected by the inadequate access to treatment in
these countries [25].
In the period under review (2001–2014), the
hospitalization rate was equal to 674/100,000 and to 15.
5/100,000 inhabitants in the < 1 year and 1–4 years age
classes, respectively. These results are in line with some
published data for the most involved age groups even if
other studies reported significant differences in
hospitalization rates.
A retrospective survey on hRSV hospital admissions
[26] was carried out in Sweden evaluating < 5 years of
age children, who were hospitalized in 2004–2011. This
survey exclusively enrolled children with a hRSV diagno-
sis confirmed by lab tests and showed that most hRSV
pathologies affect children within the first year of life.
The hospitalization rate was 17.4/1000 and 0.6/1000 in
< 1 year and 1–4 years age children, respectively. A
Spanish observational study on hRSV-related hospitali-
zations demonstrated a hospitalization rate equal to
2413/100,000 in < 2 years old children. An even higher
hospitalization rate was found in infants, being equal to
4136/100,000; the average age of hospitalized subjects
was about 5.8 months [27], confirming the greater im-
pact of hRSV on < 2 years of age children, particularly
on those < 6 months of age.
A study performed in England confirmed again that
most hospitalization due to hRSV occur in the first
months of life; the median age of hospitalized children
was 3 months and a peak of hospitalizations was regis-
tered in the first month of life [28].
An Italian study evaluated the epidemiological charac-
teristics of children hospitalized for bronchiolitis in ten
consecutive seasons (2004–2014); viruses were identified
in 48% of the samples and in 32.4% of the same hRSV
was present, confirming its role in the pathogenesis of
bronchiolitis [29]. Similarly, the relevant role of hRSV as
the major etiologic agent of bronchiolitis was confirmed
by two other retrospective studies. The first one was
Fig. 3 Hospitalizations stratified by diagnosis and age class, 2001–2014
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performed on < 12 months of life hospitalized children in
2004–2013 in a hospital in central Italy [30] and the other
on < 15 years old children hospitalized for acute respira-
tory syndrome in the period 2008–2009; hRSV was identi-
fied in 31.3 and 34.1% of cases, respectively [31].
Similarly to this study, another retrospective research
conducted in Spain [32] on hRSV bronchiolitis hospitali-
zations in < 1 year of age children between 2004 and
2012 confirmed an average lenght of stay of less than a
week.
Compared to the above mentioned studies,
hospitalization rates for hRSV and hRSV bronchiolitis in
our study resulted much lower. The explanation for this
inconsistency may be related to the lack of laboratory con-
firmation of the etiological diagnosis of infections. In Italy,
hRSV diagnosis is mostly performed, on a clinical basis,
without performing a direct diagnosis on nasopharyngeal
swab. This probably implies a great underestimation of
the pathology in hospitals; for the same reason, several
hRSV-related diseases are not correctly classified (e.g.
bronchiolitis by other viruses, ICD9-CM code 466.19).
In addition, in Italy the available studies that investi-
gated the genetic diversity of circulating hRSV-A strains
are limited, for example, in the period 1996–2006 [33],
and in the 2010/11, 2011/12, and 2012/13 epidemic sea-
sons [34].
hRSV vaccination could be the most effective means of
prevention addressed to several subjects: pregnant
women, newborns, < 6 months of age children, children
of different ages (e.g. > 6 months to 2 years, 2–5 years
and school children), > 60 years old subjects and im-
munocompromised people [9, 35]. There are several
types of vaccine under development: live attenuated,
subunit, and vectored vaccines [20]. The preventive ap-
proach through vaccination could be a useful tool espe-
cially for the extreme age classes, such as infants and the
elderly, when the immaturity of the immune system in
the first case or the immunosenescence in the second
can predispose to a serious hRSV infection [36]. The de-
velopment of the hRSV vaccine has been hampered by
the “enhanced respiratory disease” (ERD) following nat-
ural infection in naïve children previously vaccinated
with the formalin inactivated vaccine; ERD was probably
related to the deposition of lung immune complexes
and/or an imbalance of the immune response, with a
Th2-biased response [37]. Ideally, a hRSV vaccine should
stimulate mucosal immunity, activate the Th1 response
to promote virus clearance and prevent ERD, and induce
the production of neutralizing antibodies [37].
The attenuated live vaccine would offer some benefits,
especially in younger children: it does not cause vaccine-
associated disease, stimulates a broad immune response
(innate and acquired, humoral and cellular, at systemic
and respiratory level), could be administered intranasally
(without need for puncture) replicating in the upper re-
spiratory tract of young children despite the presence of
neutralizing maternal antibodies [20, 38].
While traditional vaccines mainly induce neutraliz-
ing antibodies to protect against pathogens with a
complex life cycle or high genetic instability, in this
case, it is also crucial to activate the cell-mediated
adaptive immune response (T lymphocytes, in par-
ticular cytotoxic CD8 + T lymphocytes). In the case of
hRSV, some experimental studies have shown that
while the presence of neutralizing antibodies protects
only partially from severe pathology [39], the avail-
ability of pre-existing CD8 + T lymphocytes at intrae-
pithelial level is related to a lesser severity of the
pathology [40]; in other words, there is the need to
stimulate both humoral and cellular immune
response.
Genetic vaccines are able to induce this type of immune
response. In such vaccines, the gene corresponding to the
antigen of interest (transgene) is inserted into the genome
of “vectors”, such as recombinant viruses. Among the dif-
ferent classes of viruses evaluated as carriers for genetic
vaccines, Adenoviruses have shown to have a high-
efficiency ability to infect mammalian cells, avoiding any
integration into the human genome and stimulating, in
addition to humoral and cell-mediated immune response,
also the innate response through the pathogens-associated
molecular patterns (PAMPs). Also in the case of the hRSV
vaccine, vaccines based on recombinant vectors could in-
duce the production of mRNA and antigenic proteins
within guest cells as well as a humoral and cellular
response. Various hRSV genes are candidates for this
approach, in particular the gene for proteins F, G, N
and M2–1 [41].
Vaccines based on subunits proteins would most likely
evoke an Th2-biased response and be characterized by a
pulmonary infiltrate. Genetic vaccines, on the other
hand, have a lower risk of inducing vaccine-associated
pathology because they behave like a live virus, produ-
cing antigens at intracellular level and activating a Th1
immune response [42].
The new European Medicines Agency (EMA) guide-
lines [43] address the development of RSV vaccines fo-
cusing on the assessment of their safety and efficacy in
subjects at high risk of developing a lower respiratory
tract infection or a severe hRSV disease, as well as the
opportunity of immunization of pregnant women. Simi-
larly to other vaccinations already recommended for
pregnant women (flu vaccine and dTap) it is expected
that women will be vaccinated in the third trimester to
maximize the amount of maternal antibody transferred
to the foetus. Dose regimen selection for pregnant
women may be based on maximizing the difference in
neutralising antibody titres in cord blood between
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infants born to vaccinated and unvaccinated mothers
whilst maintaining an acceptable safety profile.
Pending the conclusion of ongoing clinical trials on
different hRSV vaccine types, it is extremely important
to have updated data on the impact of hRSV-related
pathologies in the various age groups. Certainly the fre-
quent lack of laboratory diagnosis implies a significant
underdiagnosis/underreporting rate, and this also has an
impact on the evaluation of hRSV-related hospitaliza-
tions. Even if hospital admissions represent only a part,
albeit the most clinically relevant, of the total of hRSV
infections, the data from this study confirm the relevant
impact of hRSV, especially in the neonatal and pediatric
age, in our country.
This observational study is the only survey that
evaluates the impact of hRSV-related pathologies in
terms of hospitalization in the Italian population. The
study also covers a very large time frame (2001–2014).
However, it evaluates hRSV-related hospitalizations (hRSV
bronchiolitis, hRSV and hRSV pneumonia) referring only
to the main diagnosis inserted in the HDRs. No hospitali-
zations have been considered where hRSV-related
pathologies has been included as secondary diagnosis
in HDRs and this could result in an underestimation
of cases, particularly of those with respiratory failure as
primary diagnosis and hRSV-bronchiolitis as secondary
diagnosis.
Conclusions
This study highlights that the impact of hRSV on the
pediatric population in the age class 0–4 years is high,
particularly in the first year of life, however, RSV also af-
fects the elderly population, in particular in southern
Italy. In the evaluated period (2001–2014), the
hospitalization rate was equal to 674/100,000 and to 15.
5/100,000 inhabitants in the < 1 year and 1–4 years age
classes, respectively. These results are in line with other
published data and contribute to confirm that hRSV is a
global health issue. For this reason as well as for the
promising development of new vaccines, the WHO has
called for an active surveillance program of hRSV-
related infections.
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